Abstract
In adult gender dysphoric natal males, where full development of male secondary sexual characteristics has already taken place, the goal of cross-sex hormonal therapy is the suppression of testosterone secretion to achieve regression of male characteristics and the development of feminine secondary sexual characteristics. For this reason, in transwomen an almost complete suppression of endogenous androgen production and action with combined administration of estrogens is required. The aim of therapy is to maintain hormone levels within the normal physiological range for the individual’s desired gender. Practice guidelines describe eligibility for puberty suppression in adolescents that have met the criteria for gender dysphoria and that have experienced at least Tanner stage 2 puberty. In these subjects if dysphoria persists, cross-hormonal therapy is generally started after 16 years of age.
References
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013. Available from: dsm.psychiatryonline.org. Accessed 1 June 2016.
Blankenstein MA, Verheijen FM, Jacobs JM, et al. Occurrence, regulation, an significance of progesterone receptors in human meningioma. Steroids. 2000;65:795–800.
Bunck MC, Debono M, Giltay EJ, et al. Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages. BMJ Case Rep. 2009;2009:bcr02.
Cea-Soriano L, Blenk T, Wallander M-A, et al. Hormonal therapies and meningioma: is there a link? Cancer Epidemiol. 2012;36:198–205.
Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual transgender, and gender-nonconforming people, version 7. Int J Transgenderism. 2011;13:165–232.
Cunha FS, Domenice S, Câmara VL, et al. Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy. Andrologia. 2015;47(6):680–4.
Dahl M, Feldman JL, Goldberg J, et al. Endocrine therapy for transgender adults in British Columbia: suggested guidelines. Vancouver: Transgender Health Program; 2006. Available from: http://transhealth.vch.ca/. Accessed 1 June 2016.
De Vries AL, Cohen-Kettenis PT. Clinical management of gender dysphoria in children and adolescents: the Dutch approach. J Homosex. 2012;59:301–20.
Ettner R. Care of the elderly transgender patient. Curr Opin Endocrinol Diabetes Obes. 2013;20(6):580–4.
Fisher AD, Ristori J, Bandini E, et al. Medical treatment in gender dysphoric adolescents endorsed by SIAMS-SIESIEDP- ONIG. J Endocrinol Investig. 2014;37:675–87.
Gava G, Cerpolini S, Martelli V, et al. Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness. Clin Endocrinol. 2016;85(2):239–46.
Gazzeri R, Galarza M, Gazzeri G. Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. N Engl J Med. 2007;357:2411–2.
Gil M, Oliva B, Timoner J, et al. Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br J Clin Pharmacol. 2011;72:965–8.
Gooren LJ. Clinical practice. Care of transsexual persons. N Engl J Med. 2011;364:1251–7.
Gulmez SE, Lassen AT, Aalykke C, et al. Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study. Br J Clin Pharmacol. 2008;66:294–9.
Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2009;94:3132–54.
Knezevich EL, Viereck LK, Drincic AT. Medical management of adult transsexual persons. Pharmacotherapy. 2012;32:54–66.
Meriggiola MC, Bremner WJ, Costantino A, et al. An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertil Steril. 1997;68(5):844–50.
Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab. 2003;88:3467–73.
Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2008;159:197–202.
Murad MH, Elamin MB, Garcia MZ, et al. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin Endocrinol (Oxford). 2010;72:214–31.
Ott J, Kaufmann U, Bentz EK, et al. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertil Steril. 2010;93:1267–72.
Royal College of Psychiatrists. Good practice guidelines or the assessment and treatment of adults with gender dysphoria. Royal College of Psychiatrists, 2013. Available from: http://www.rcpsych.ac.uk/usefulresources/publications/collegereports/cr/cr181.aspx. Accessed 18 June 2016.
Savidou I, Deutsch M, Soultati AS, et al. Hepatotoxicity induced by cyproterone acetate: a report of three cases. World J Gastroenterol. 2006;12:7551–5.
Schagen SE, Cohen-Kettenis PT, Delemarre-van de Waal HA, et al. Efficacy and safety of gonadotropin-releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents. J Sex Med. 2016;13(7):1125–32.
Seal LJ, Franklin S, Richards C, et al. Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens. J Clin Endocrinol Metab. 2012;97:4422–8.
Spack NP. Management of transgenderism. JAMA. 2013;309:478–84.
Tangpricha V, Ducharme SH, Barber TW, et al. Endocrinologic treatment of gender identity disorders. Endocr Pract. 2003;9:12–21.
Ter Wengel PV, Martin E, Gooren L, et al. Meningiomas in three male-to-female transgender subjects using oestrogens/progestogens and review of the literature. Andrologia. 2016. doi:10.1111/and.12550. [Epub ahead of print].
Toorians AW, Thomasse MC, Zweegman S, et al. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab. 2003;88(12):5723–9.
Wigertz A, Lonn S, Hall P, et al. Reproductive factors and risk of meningioma and glioma. Cancer Epidemiol Biomark Prev. 2008;17:2663–70.
Wilson AC, Meethal SV, Bowen RL, et al. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig Drugs. 2007;16:1851–63.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this entry
Cite this entry
Gava, G., Seracchioli, R., Meriggiola, M.C. (2017). Therapy with Antiandrogens in Gender Dysphoric Natal Males. In: Simoni, M., Huhtaniemi, I. (eds) Endocrinology of the Testis and Male Reproduction. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-44441-3_42
Download citation
DOI: https://doi.org/10.1007/978-3-319-44441-3_42
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-44440-6
Online ISBN: 978-3-319-44441-3
eBook Packages: MedicineReference Module Medicine